troglitazone has been researched along with Psoriasis in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether treatment with troglitazone, a currently available thiazolidinedione used to treat diabetes mellitus, has an effect on psoriasis in normoglycemic patients and whether ligands for PPARgamma have an effect on models of psoriasis." | 9.09 | Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. ( Benson, SC; Chi, Y; Ellis, CN; Fisher, GJ; Kurtz, TW; Pershadsingh, HA; Varani, J; Zeigler, ME, 2000) |
| "To assess whether treatment with troglitazone, a currently available thiazolidinedione used to treat diabetes mellitus, has an effect on psoriasis in normoglycemic patients and whether ligands for PPARgamma have an effect on models of psoriasis." | 5.09 | Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. ( Benson, SC; Chi, Y; Ellis, CN; Fisher, GJ; Kurtz, TW; Pershadsingh, HA; Varani, J; Zeigler, ME, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pershadsingh, HA | 2 |
| Sproul, JA | 1 |
| Benjamin, E | 1 |
| Finnegan, J | 1 |
| Amin, NM | 1 |
| Ellis, CN | 1 |
| Varani, J | 1 |
| Fisher, GJ | 1 |
| Zeigler, ME | 1 |
| Benson, SC | 1 |
| Chi, Y | 1 |
| Kurtz, TW | 1 |
1 trial available for troglitazone and Psoriasis
| Article | Year |
|---|---|
Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation.
Topics: Adult; Animals; Antineoplastic Agents; Cell Differentiation; Chromans; DNA Primers; Female; Humans; | 2000 |
1 other study available for troglitazone and Psoriasis
| Article | Year |
|---|---|
Treatment of psoriasis with troglitazone therapy.
Topics: Adult; Aged; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Immunosuppressive Age | 1998 |